Joel Gallant, MD, MPH
Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF; Biktarvy, Gilead) could be a long-term option for older adults with HIV (HIV Med 2022 May 8 https://doi.org/10.1111/ hiv.13319).
“Clinical trial data in older people with HIV are unavailable for many treatment regimens,” said the study’s corresponding author, Joel Gallant, MD, MPH, the executive director of Global Medical Affairs for Gilead Sciences, in Santa Fe, N.M.